LFG
MBX

Larson Financial Group’s MBX Biosciences MBX Stock Holding History

Larson Financial Group’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.71K Hold
49
– – ﹤0.01% 3018
2026
Q1 		$1.46K Buy
+49
New +$1.67K ﹤0.01% 3056

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Larson Financial Group's MBX Position: Q2 2026 in Review

Larson Financial Group held its MBX Biosciences (MBX) position steady in Q2 2026 at 49 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #3018.

Larson Financial Group first reported a position in MBX in Q1 2026 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Larson Financial Group held 49 shares of MBX Biosciences worth $2.71K as of Q2 2026.
  • Larson Financial Group left its MBX Biosciences share count unchanged in Q2 2026.
  • MBX Biosciences made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3018 holding.
  • Larson Financial Group first reported a position in MBX Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.